(DCTH) Delcath Systems - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US24661P8077
DCTH: Cancer, Treatment, Chemotherapy, Liver, Delivery, System
Delcath Systems, Inc. (NASDAQ:DCTH), a leader in interventional oncology, specializes in innovative treatments for primary and metastatic liver cancers. The companys flagship product, HEPZATO KIT, represents a significant advancement in targeted chemotherapy delivery. This system combines melphalan with a hepatic delivery mechanism designed to maximize therapeutic impact while minimizing systemic exposure, thereby reducing adverse side effects. HEPZATO is currently under evaluation in the FOCUS clinical trial, which is investigating its efficacy in treating metastatic hepatic dominant Uveal Melanoma, with a primary focus on objective response rate. Beyond its investigational use, Delcath also markets the CHEMOSAT Hepatic Delivery System in Europe, enabling medical centers to administer melphalan for a range of liver cancers under approved indications. Established in 1988, Delcath is headquartered in New York, New York, and maintains a strong presence in both the U.S. and European markets. Web URL: https://www.delcath.com.
From a stock performance perspective, Delcath Systems, Inc. (NASDAQ:DCTH) is currently trading at $13.95, with a 20-day average volume of 335,331 shares. The stocks short-term technical outlook is mixed, as the 20-day SMA ($15.60) and 50-day SMA ($14.03) indicate recent downward pressure, while the 200-day SMA ($10.21) reflects longer-term upside momentum. The ATR of 0.81 signals moderate volatility. On the fundamental side, the companys market cap stands at $538.66M, with a forward P/E of 106.38, reflecting investor expectations of future earnings growth. The P/B ratio of 62.85 highlights a premium valuation relative to book value, while the P/S ratio of 23.79 underscores the markets confidence in the companys revenue potential. However, the lack of reported RoE suggests that profitability remains a key area of focus for investors.
3-Month Forecast: Based on the intersection ofAdditional Sources for DCTH Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
DCTH Stock Overview
Market Cap in USD | 479m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2018-05-29 |
DCTH Stock Ratings
Growth 5y | 17.8% |
Fundamental | -31.9% |
Dividend | 0.0% |
Rel. Strength Industry | 216 |
Analysts | 4.67/5 |
Fair Price Momentum | 11.42 USD |
Fair Price DCF | - |
DCTH Dividends
No Dividends PaidDCTH Growth Ratios
Growth Correlation 3m | 48.3% |
Growth Correlation 12m | 96% |
Growth Correlation 5y | -36.7% |
CAGR 5y | 5.82% |
CAGR/Max DD 5y | 0.06 |
Sharpe Ratio 12m | 0.42 |
Alpha | 200.67 |
Beta | 2.61 |
Volatility | 72.70% |
Current Volume | 220.8k |
Average Volume 20d | 314.2k |
As of March 14, 2025, the stock is trading at USD 12.08 with a total of 220,753 shares traded.
Over the past week, the price has changed by -8.62%, over one month by -25.80%, over three months by -0.25% and over the past year by +215.40%.
Probably not. Based on ValueRay Fundamental Analyses, Delcath Systems (NASDAQ:DCTH) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -31.92 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DCTH as of March 2025 is 11.42. This means that DCTH is currently overvalued and has a potential downside of -5.46%.
Delcath Systems has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy DCTH.
- Strong Buy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, DCTH Delcath Systems will be worth about 13.5 in March 2026. The stock is currently trading at 12.08. This means that the stock has a potential upside of +11.51%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 22.2 | 83.5% |
Analysts Target Price | 21.3 | 76.6% |
ValueRay Target Price | 13.5 | 11.5% |